Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Bristol Myers Squibb (BMS) has agreed to acquire Forbius, a Montréal-based clinical-stage biopharmaceutical company developing biotherapeutics for treating cancer and fibrotic diseases. Financial terms were not disclosed. Forbius has developed a...

A roundup of news from Denmark (Novo Nordisk), Germany (Evotec, Novo Nordisk), Japan (Takeda), and the US (Lupin, Sun Pharma, Alnylam, Teva, and others). Denmark Novo Nordisk To Invest $135 M in Danish Production FacilitiesNovo Nordisk plans to...

Sanofi has agreed to acquire Principia Biopharma, a South San Francisco, California-based clinical-stage biopharmaceutical company focused on immune-mediated diseases, for $3.68 billion. Principia Biopharma is developing Bruton’s tyrosine kinase...

Mylan has launched a generic version of Biogen's Tecfidera (dimethyl fumarate), a drug for treating relapsing multiple sclerosis (MS). Tecfidera is Biogen’s top-selling drug with 2019 global sales of $4.4 billion. Mylan is launching dimethyl...

Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Cambridge, Massachusetts-based company developing biosimilars and new biologics for rare immune-mediated diseases, for $6.5 billion. Momenta’s lead asset is...

Bristol Myers Squibb (BMS) and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have formed a collaboration, worth up to $475 million, for Dragonfly’s immunotherapy candidate, DF6002, for...

Eisai's US subsidiary, Eisai Inc., has announced plans to re-locate its US headquarters in Woodcliff Lake, New Jersey to the former Roche headquarters campus in Nutley, New Jersey. The move is expected to be completed in late 2021 and will transfer...